...For different cohorts: Cohort A: Patients with locally advanced or metastatic NSCLC who have been confirmed by cytology or histology as inoperable or concurrent radiotherapy and chemotherapy, meet any of the following criteria: 1) Have not previously received systemic treatment for advanced or metastatic disease, except for patients with known EGFR sensitive mutations and ALK rearrangements; 2) After the failure of first-line platinum dual-drug chemotherapy; 3) Patients with known EGFR sensitive mutations or ALK rearrangements must have received at least one EGFR or ALK inhibitor treatment progression or intolerance; Cohort B: Patients with inoperable locally advanced, recurrent/metastatic gastric or gastroesophageal junction adenocarcinoma confirmed by cytology or histology, meeting any of the following criteria: 1) Locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma (including signet ring cell carcinoma, mucinous adenocarcinoma, liver-like adenocarcinoma) that is newly diagnosed as unresectable, except for patients diagnosed as HER2-positive; 2) Unresectable or metastatic gastric/esophageal junction cancer with high microsatellite instability (MSI-H) or mismatch repair defect (dMMR) that has progressed after frontline treatment; 3) Locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma that failed the second-line standard treatment, and PD-L1 CPS>1; Cohort C: Inoperable locally advanced recurrent or metastatic esophageal squamous cell carcinoma, meeting all the following criteria: 1) The previous first-line standard treatment failed; 2) Known endoscopes that tend to be completely obstructed and require interventional therapy to relieve the obstruction cannot be included; 3) After stent implantation in the esophagus or trachea, it cannot be included; 4) Patients who have a higher risk of bleeding or perforation due to the obvious invasion of the tumor into the adjacent organs of the esophageal lesion (aorta or trachea), or those who have formed a fistula, are not eligible; Cohort D: Inoperable patients with locally advanced, recurrent/metastatic hepatocellular carcinoma, the diagnosis of hepatocellular carcinoma is confirmed by histology/cytology or the patients with liver cirrhosis meet the clinical diagnosis of American Society for the Study of Liver Diseases (AASLD) hepatocellular carcinoma standard. ...

...Have a histologically confirmed diagnosis of gastric adenocarcinoma and have been determined to be dMMR or MSI-H through immunohistochemistry or PCR, or PDL1 (22C3) CPS ≥ 10 through immunohistochemistry; 4. ...

Among four patients with mismatch repair deficiency/microsatellite instability-high (dMMR/MSI-H) lesions, two achieved partial remission, and two displayed stable disease, resulting in a DCR of 100%....The application of sintilimab-based regimens achieved good disease control and tolerability for the real-world treatment of advanced G/GEJAC....Patients with dMMR/MSI-H lesions may also benefit from sintilimab-based regimens.